Semaglutide is an injectable medication that treats type 2 diabetes and obesity by regulating blood sugar levels. A ...

While weight loss medications can deliver significant results, our bodies eventually adapt to everything. And many people end ...

Researchers warned that to achieve such reductions, greater uptake of the medication among indicated patients is needed.

Injectable semaglutide has better bioavailability, researchers say, but the many patients who want an oral drug are an unmet ...

A large clinical trial, co-led by researchers at the UNC School of Medicine, has shown that the popular weight-loss drug ...

Semaglutide use associated with increased risk for NAION at the 2-, 3-, and 4-year time point from the index date.

Not only does it combat diabetes and aid in weight loss, but it also safeguards heart health in all patients at high ...

Semaglutide associated with increased walking distance in patients with symptomatic peripheral artery disease and type 2 diabetes. (HealthDay News) — For patients with symptomatic peripheral ...

Building on results of the landmark SELECT trial, SCORE shows cardiovascular (CV) risk reduction with use of semaglutide 2.4 mg in a real-world environment 1 SCORE is a retrospective ...

Semaglutide 2.4 mg reduced total cardiovascular events by 22% in people with established cardiovascular disease (CVD) and overweight or obesity without diabetes. 1 Obesity directly leads to ...

Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention ...